Chordate Medical Holding AB (OSTO:CMH) EBITDA: kr-23.37 Mil (TTM As of Jun. 2025)


OSTO:CMH Chordate Medical Holding AB OSTO:CMH
46 GF Score
Price kr0.16
GF Value kr26.18
! 6 Warning Signs
View Full Analysis

What is Chordate Medical Holding AB EBITDA?

Chordate Medical Holding AB OSTO:CMH -60.40% 46 EBITDA is kr-23.37 Mil as of Jun. 2025. GuruFocus rates OSTO:CMH with a GF Score™ of 46/100 and a GF Value™ of kr26.18. The stock has 6 warning signs investors should review.

Chordate Medical Holding AB's EBITDA for the three months ended in Jun. 2025 was kr-4.80 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was kr-23.37 Mil.

During the past 3 years, the average EBITDA Growth Rate was -7.40% per year. During the past 5 years, the average EBITDA Growth Rate was -9.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 10 years, the highest 3-Year average EBITDA Growth Rate of Chordate Medical Holding AB was -3.50% per year. The lowest was -56.90% per year. And the median was -10.50% per year.

Chordate Medical Holding AB's EBITDA per Share for the three months ended in Jun. 2025 was kr-1.78. Its EBITDA per share for the trailing twelve months (TTM) ended in Jun. 2025 was kr-16.79.

During the past 3 years, the average EBITDA per Share Growth Rate was -475.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 19.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 10 years, the highest 3-Year average EBITDA per Share Growth Rate of Chordate Medical Holding AB was 94.10% per year. The lowest was -739.00% per year. And the median was 22.20% per year.

Chordate Medical Holding AB  (OSTO:CMH) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Chordate Medical Holding AB EBITDA Related Terms


Chordate Medical Holding AB EBITDA Historical Data

* Premium members only.

The historical data trend for Chordate Medical Holding AB's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordate Medical Holding AB EBITDA Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.85 -20.20 -25.57 -26.73 -25.03

Chordate Medical Holding AB Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.58 -5.13 -8.04 -5.40 -4.80

OSTO:CMH vs ABT, SYK, MDT: EBITDA Comparison

For the Medical Devices subindustry, Chordate Medical Holding AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB EV-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's EV-to-EBITDA falls into.


OSTO:CMH
46GF Score
Chordate Medical Holding AB OSTO:CMH
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Chordate Medical Holding AB's EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Chordate Medical Holding AB's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2024, Chordate Medical Holding AB's EBITDA was kr-25.03 Mil.

Chordate Medical Holding AB's EBITDA for the quarter that ended in Jun. 2025 is calculated as

Chordate Medical Holding AB's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Jun. 2025, Chordate Medical Holding AB's EBITDA was kr-4.80 Mil.

EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-23.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of kr-23.37 Mil mean?
Chordate Medical Holding AB (OSTO:CMH) has a EBITDA of kr-23.37 Mil as of Jun. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Chordate Medical Holding AB.
Is Chordate Medical Holding AB's EBITDA too high?
Chordate Medical Holding AB's current EBITDA is kr-23.37 Mil. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's EBITDA compare to ABT and SYK?
Chordate Medical Holding AB's EBITDA of kr-23.37 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Devices & Instruments company?
A good EBITDA depends on the Medical Devices & Instruments industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Chordate Medical Holding AB. Chordate Medical Holding AB's current EBITDA is kr-23.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current EBITDA of kr-23.37 Mil. The stock's GF Value™ is kr26.18, compared to a current price of kr0.16 — trading 99.4% below its estimated fair value. The current EBITDA is kr-23.37 Mil. Chordate Medical Holding AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current EBITDA is kr-23.37 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chordate Medical Holding AB (OSTO:CMH) Overvalued in 2026?

Based on GuruFocus' analysis, Chordate Medical Holding AB stock appears to be undervalued. The current stock price of kr0.16 is trading 99.4% below its estimated GF Value™ of kr26.18.

Key valuation signals for OSTO:CMH:

  • EBITDA: kr-23.37 Mil
  • GF Value™: kr26.18 vs. price of kr0.16 (99.4% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the OSTO:CMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chordate Medical Holding AB Business Description

Address Farogatan 33, 164 51 Kista, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score

Get the complete analysis for OSTO:CMH

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.16
Price
kr26.18
GF Value